ENHANZE® drug delivery technology: a novel approach to subcutaneous administration using recombinant human hyaluronidase PH20

• Những tác giả chính: Kenneth W. Locke (Tác giả), Daniel C. Maneval (Tác giả), Michael J. LaBarre (Tác giả)
• Định dạng: Sách
• Được phát hành: Taylor & Francis Group, 2019-01-01T00:00:00Z.
• Những chủ đề: article
• Truy cập trực tuyến: Connect to this object online.

ENHANZE® drug delivery technology is based on the proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20; Halozyme Therapeutics, Inc.) that facilitates the subcutaneous (SC) delivery of co‐administered therapeutics. rHuPH20 works by degrading the glycosaminoglycan hyaluronan (HA), which pl...